Literature DB >> 15816970

Callosal bisection and transcallosal secondary antiepileptogenesis.

Juhn A Wada1.   

Abstract

More than 28,000 neuroscientists and 3,000 epileptologists gathered at their respective 2001 meetings of the Society for Neuroscience and the American Epilepsy Society. Yet only six articles, one directly and five indirectly, discussed the corpus callosum (CC). Is not this in itself a remarkable finding? Are there no mysteries left? The reality is that considerable uncertainties exist regarding the rationale for callosal bisection (CCB) that causes contrasting effects (i.e., amelioration of generalized seizure, at times leading to freedom from seizure, and intensification of postoperatively fragmented seizure, at times leading to status epilepticus). Similarly, the clinical relevance of EEG mirror focus formation, an experimentally well-established transcallosal consequence of partial cortical epileptogenesis, continues to be debated. This presentation revisits these unresolved issues (a) to gain insight into the dynamic role played by the CC in medically refractory epilepsy, and (b) to promote the development of antiepileptogenic tools that are currently unavailable.

Entities:  

Mesh:

Year:  2005        PMID: 15816970     DOI: 10.1111/j.0013-9580.2005.461002.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Non-invasive treatment options for focal cortical dysplasia.

Authors:  Ting-Ting Wang; Dong Zhou
Journal:  Exp Ther Med       Date:  2016-02-22       Impact factor: 2.447

Review 2.  Secondary Epileptogenesis: Common to See, but Possible to Treat?

Authors:  Yujia Shen; Yiwei Gong; Yeping Ruan; Zhong Chen; Cenglin Xu
Journal:  Front Neurol       Date:  2021-12-06       Impact factor: 4.003

3.  On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy.

Authors:  Esther Krook-Magnuson; Caren Armstrong; Mikko Oijala; Ivan Soltesz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.